Latest From Terumo Corp.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Terumo is acquiring the vascular therapy company to boost its AAA graft business.
TCT 2019: Evolve Short DAPT And Model U-SUS Study Show Short DAPT Was Comparable To Longer-Term DAPT
Data from two studies that looked at the safety of three-months dual antiplatelet therapy versus longer-term DAPT therapy, presented on 26 September at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, showed non-inferiority for short-term DAPT.
Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.
- Large Molecule
- Implantable Devices
- Surgical Equipment & Devices
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Renal System
- Wound Healing & Tissue Repair
- Pacific Rim
- Parent & Subsidiaries
- Terumo Corp.
- Senior Management
Shinjiro Sato, Pres. & CEO
Ryo Nishihata, Chief Accounting & Financial Officer
- Contact Info
Phone: (81) 3-3374-8111
2-44-1 Hatagaya, Shibuya-ku
Tokyo, 151 0072
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.